FDA Approves Denali Therapeutics' Avlayah To Treat Hunter Syndrome

Denali Therapeutics has received FDA approval for its drug Avlayah, which is designed to treat the neurologic manifestations of Hunter Syndrome. This approval marks a significant milestone for the company in the rare disease market. The stock ticker for Denali Therapeutics is DNLI.